Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
News Alert: FDA highlights safety issue with leadless pacemakers
Thursday, November 18, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA highlights safety issue with leadless pacemakers, focusing on Medtronic’s Micra

All pacemakers are associated with a risk of cardiac perforation, the agency said, but perforation-related complications appear to be more severe with leadless pacing systems.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

FDA highlights safety issue with leadless pacemakers, focusing on Medtronic’s Micra

Share on Twitter Share on Facebook Share on Linkedin
All pacemakers are associated with a risk of cardiac perforation, the agency said, but perforation-related complications appear to be more severe with leadless pacing systems.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

FDA impressed by AI-powered blood test | Comparing TAVR valves | A big approval for GE HealthCare | New HCM drug delivers
Radiation protection in the cath lab | Imaging catheters removed from market over safety risks | CT-guided PCI
When TAVR valves fail | Cardiology groups share a tariff warning | Bariatric surgery & the heart | GE HealthCare debuts MRI tech
Tricuspid outcomes keep improving | BATMAN helps cardiologists | IVL & TAVR | Robotic mitral valve repair
A new use for IVL | TAVR & SAVR in patients with low-flow, low-gradient AS | Obicetrapib linked to substantial LDL-C reductions
Week in Review: Tirzepatide bests semaglutide | TAVR approved for asymptomatic patients | BATMAN limits complications
Highlights from SCAI 2025: Meet the new president | Tirzepatide vs. semaglutide | Cannabis & heart failure | CT-guided PCI

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …80
    • Page 81
    • Page 82
    • Page 83
    • Current page 84
    • Page 85
    • Page 86
    • Page 87
    • Page 88 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme